Are CSF neopterin levels a marker of disease activity in multiple sclerosis?

Kostas Kapinas¹, Magda Tsolaki², Demetrios Zaphiriou², Philip Grammaticos³, Eleni Dedussi³
¹3rd Department of Neurology, Aristotle University of Thessaloniki, Greece
²General Papanikolaou Hospital, Thessaloniki, Greece
³Nuclear Department, AHEPA Hospital of Thessaloniki, Greece

Abstract

The study aimed to evaluate neopterin levels in cerebro-spinal fluid (CSF) as a marker of disease activation and progression of multiple sclerosis (MS).

Neopterin, a substance known to be released from macrophages and monocytes at increased rates in cellular immune reactions, was investigated by radioimmunoassay, in the CSF of 19 patients with MS during exacerbations of the disease, in 34 patients with other neurological diseases (OND) and in 20 normal subjects used as controls. Poser’s criteria were used for the diagnosis of MS.

Although elevated neopterin levels in the CSF of patients with MS during exacerbations have been reported by other investigators, we found such elevation in only 4 out of 19 patients with MS (21%), in 5 out of 34 patients with OND (14.7%), and in none of the control group. Student’s t-test was used for statistical analysis. There was no significant difference in the CSF values of the MS patients, the patients with OND (p > 0.05) or the controls. These results indicate that neopterin levels in CSF may not be considered a marker of disease activity in MS.

Key words: multiple sclerosis, neopterin, cerebro-spinal fluid

Introduction

Neopterin is a pyrazino-2,3 d-pyrimidine derivative formed from quanosintriphosphate (GTP) in the synthesis pathway of biopterin, which acts as a cofactor in neurotransmitter synthesis — i.e., in hydroxylation of phenylalanine, tyrosine and tryptophan [1, 2]. It is released from monocytes and macrophages after stimulation in vitro by gamma interferon (gamma IFN) from activated T cells [3]. Release of neopterin from peripheral blood mononuclear cells in vitro was shown to be induced through activation of T cells stimulated by alloantigens or by virally modified autologous cells [4].

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). Although the etiology of MS is still unclear, pathology studies have indicated that infiltrating cells are composed mainly of activated T cells and monocytes-macrophages. Increased neopterin levels in the CSF of patients with MS during exacerbations have been reported [5, 6], while others did not find differences in CSF levels of neopterin in patients with MS, those with other neurological diseases and healthy controls [7]. Increased neopterin excretion in serum and urine has also been described in patients with viral infections [8, 9], rheumatoid arthritis, systemic lupus erythematosus, coeliac disease [10], malaria [11] and certain tumours [8]. Neopterin has also been used as a biochemical marker of cellular immune response and T-cell activation [1, 11] and to follow the clinical course during different therapeutic trials — e.g., with interleukin-2 in patients with acquired immune deficiency syndrome (AIDS) [12].

The purpose of this study was to determine if neopterin levels are increased in the CSF and if neopterin is a valuable marker of acute cellular immune response and should represent an objective way to monitor disease activity in MS.

Material and methods

Patients

Multiple sclerosis. Nineteen patients (11 female, 8 male, aged 25 to 60 years; mean age 40.4 years) were clinically diagnosed with MS as defined by the criteria of Poser, et al. [13] None of the patients was treated with immunotherapeutic or other related drugs during the study.

Control Subjects with OND. Fifty-four patients (20 female, 34 male, aged 21 to 81 years; mean age 53.7 years) with OND were studied. Of these patients 9 were with cerebral infarctions, 4 with Guillain-Barre syndrome, 4 with polyneuropathy, 8 with dementia, 4 with paraparesis, 2 with Parkinson’s disease, 2 with meningioma and 1 with acoustic neurinoma.
Healthy Control Subjects. Twenty individuals (8 female, 12 male, aged 29 to 53 years; mean age 45.7 years) with tension headache or psychoneurotic disorders constituted a control group for establishing the upper reference level of neopterin concentrations in CSF.

CSF samples were taken between 10:00 and 12:00 hours. 15 ml of CSF was obtained by lumbar puncture. Cells, protein and glucose levels in CSF were measured. The remaining CSF was stored at 20°C in a refrigerator where it was protected against light until use (in a Symbol CR “Symbol” C). Oligoclonal bands in serum and CSF were determined by agarose gel electrophoresis. Neopterin in CSF was measured with a standard radioimmunoassay (RIA) within 6 months after sampling.

The upper reference limit of neopterin in CSF was 2.5 ng/ml. Total and differential counts of CSF cells were also performed. Determinations of IgG and albumin were carried out on unconcentrated CSF. Oligoclonal bands in serum and CSF were tested by agarose gel electrophoresis. Before electrophoresis, CSF was concentrated 80–100 times using an Amicon B10 macrosolute concentrator.

Statistical analysis
Mean neopterin levels in CSF among patients with MS and OND, and healthy control subjects were compared by the Student’s t-test and regression analysis.

Results
CSF neopterin levels of 2.5 ng/mL or higher were found in 4 (21%) of 19 patients with MS, in 5 (14.7%) of 34 patients with OND and in none of 20 healthy control subjects. The patients with OND who had an elevated CSF neopterin level included 1 of 4 with paraparesis, 1 of 4 with polyneuropathy, 1 of 4 with Guillain-Barre syndrome, 1 of 8 with dementia (vascular dementia) and 1 of 9 with stroke.

The mean CSF neopterin levels for all MS patients did not significantly differ from those of the controls or of the patients with OND (p < 0.05).

Very high or high neopterin levels were found in one patient with paraparesis (14 ng/ml), in one with cervical disc (20 ng/ml), in one with neuropathy (12 ng/ml), in one who had a history of vascular dementia and in one with stroke (3 ng/ml). Very high neopterin levels were also found in MS patients (20, 20.8, and 8.4 ng/ml).

CSF neopterin levels, protein, cells and glucose in MS patients are shown in Table 1. Mean values and standard deviation of all neopterin values in patients and controls are shown in Table 2. Normal neopterin values are up to 2.5 ng/ml.

Discussion
It is known that symptoms and signs will only partly reflect the abnormal CNS test in MS patients. This has been demonstrated when autopsy materials are tested [14, 15] and also when clinical symptoms and signs are correlated to findings from magnetic resonance imaging (MRI) [16, 17]. Jacobs et al. (1986) showed that 75% of lesions detected on MRI were clinically silent and only 5% were definitely related to symptoms and signs.

Elevated serum neopterin levels occur in several acute and chronic infections including HIV, and haematologic malignancies and also during graft rejection [18]. Serum neopterin levels in patients with OND, peripheral neuropathies or MS, who were in clinically stable condition at the time of testing, were not significantly different from levels in healthy controls. However, mean neopterin levels in patients with OND were significantly higher (p < 0.05) than levels in patients with MS [7].

In other studies, CSF levels of neopterin were higher in patients with MS during exacerbation [5, 19, 20] and in the relapsing-remitting type of the disease [21]. The significant CSF increase in neopterin described in some references was not reflected in serum [19, 22], suggesting possible intrathecal production of neopterin.

In this study we found no statistical difference in neopterin CSF levels among patients with MS and OND, and the controls. In addition, we found very high neopterin levels in 5 patients with OND: one with paraparesis, one with polyneuropathy, one with Guillain-Barre syndrome, one with vascular dementia and one with stroke. We found no explanation for this finding although it could reflect non-specific immune activation due to damage in the central nervous system or in the peripheral nerves.

Conclusion
In conclusion, it seems that determination of neopterin CSF levels cannot be used as a marker of disease activity in MS patients.
References